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Immune control of infections with viruses or intracel-
lular bacteria relies on cytotoxic CD8+ T cells that use
granzyme B (GzmB) for elimination of infected cells.
During inflammation, mature antigen-presenting
dendritic cells instruct naive T cells within lymphoid
organs to develop into effector T cells. Here, we
report a mechanistically distinct and more rapid pro-
cess of effector T cell development occurring within
18 hr. Such rapid acquisition of effector T cell function
occurred through cross-presenting liver sinusoidal
endothelial cells (LSECs) in the absence of innate im-
mune stimulation andknowncostimulatory signaling.
Rather, interleukin-6 (IL-6) trans-signaling was
required and sufficient for rapid induction of GzmB
expression in CD8+ T cells. Such LSEC-stimulated
GzmB-expressing CD8+ T cells further responded
to inflammatory cytokines, eliciting increased and
protracted effector functions. Our findings identify a
role for IL-6 trans-signaling in rapid generation of
effector function inCD8+Tcells thatmaybebeneficial
for vaccination strategies.
INTRODUCTION
The induction of T cell immunity requires innate immune activa-
tion that generates inflammation and leads to maturation of pro-
fessional antigen-presenting cells (APCs), such as dendritic cells
(DCs). Such mature APCs cross-prime naive CD8+ T cells and
elicit differentiation into cytotoxic T lymphocytes (CTLs) (Kurts
et al., 2010). Ideally, naive T cells receive membrane-associated
and soluble costimulatory signals through CD28 together with
receptors for interleukin-12 (IL-12) and type I interferon (IFN) in
addition to T cell receptor (TCR) stimulation (Curtsinger and
Mescher, 2010). Such combination of signals is necessary to
achieve optimal stimulation to induce sustained T cell prolifera-1318 Cell Reports 8, 1318–1327, September 11, 2014 ª2014 The Aution and acquisition of T cell effector function. This differentiation
process takes several days and is governed by a complex
network of transcriptional regulators that control cell prolifera-
tion, effector function, and survival (Kaech and Cui, 2012).
Effector function of CTLs is accomplished by secretion of anti-in-
fectious cytokines such as tumor necrosis factor (TNF) and IFNg
together with expression of death-inducing molecules such as
granzyme B (GzmB) or perforin that are crucial for elimination
of infected cells (Trapani and Smyth, 2002; Zhang and Bevan,
2011). Key to CTL differentiation and effector cell function
are the T-box transcription factors T-bet and eomesodermin
(Eomes) (Intlekofer et al., 2005; Pearce et al., 2003). In the
absence of T-box transcription factors, T cells fail to correctly
differentiate into functional CTLs.
IL-6 is a cytokine with pleiotropic functions that contributes to
anti-infectious immunity. IL-6 signals through the IL-6 receptor
(IL-6R) and b subunit glycoprotein 130 (gp130). IL-6R exists as
a membrane-anchored protein (classic signaling) as well as in
a soluble form (trans-signaling) that can be detected at sites of
inflammation. Because of the restricted expression of IL-6R,
many of the biological activities of IL-6 are attributed not to the
cytokine alone but to the action of a soluble complex of IL-6
and IL6R, which initiates IL-6 trans-signaling by binding to ubiq-
uitously expressed gp130 (Jones et al., 2011). IL-6 has been
shown to induce expression of acute-phase proteins, regulate
development of DCs, contribute to T helper 17 cell differentia-
tion, and foster B cell development and antibody responses
(Jones, 2005; Jones et al., 2011). A contribution of IL-6 signaling
to development of CD8+ T cell immunity beyond the induction of
inflammation has been suggested (MacLeod et al., 2011) but has
not been characterized in detail.
In vivo, priming of naive T cells by mature APCs occurs in
lymphoid tissues such as lymph nodes and spleen, which facili-
tates the encounter of antigen-loaded APCs and naive T cells in
highly specialized compartments, i.e., the T cell zones (Junt
et al., 2008). Alternatively, naive CD8+ T cells are also stimulated
outside of lymphoid tissues in peripheral organs such as the liver
(Thomson and Knolle, 2010). Here, a highly abundant population
of liver-resident cells, i.e., liver sinusoidal endothelial cellsthors
(LSECs), function as scavenger cells to clear antigens from the
circulation and as APCs to cross-present those antigens to
circulating CD8+ T cells (von Oppen et al., 2009). Naive T cell
stimulation in the liver occurs without the requirement for innate
immune stimulation and in the absence of conventional costimu-
latory signals. Such T cell stimulation by antigen-presenting
LSECs results over a period of several days in the generation
of memory T cells, thus complementing conventional memory
T cell generation induced during inflammation (Bo¨ttcher et al.,
2013). These memory T cells generated by antigen-presenting
LSECs over a period of several days did not show any direct
cytotoxic effector function and, similar to conventional memory
T cells, required combinatorial stimulation through costimulatory
receptors for reactivation (Bo¨ttcher et al., 2013).
Here, we report on the discovery of a mechanism that facili-
tates rapid induction of GzmB expression and effector function
within 18 hr in naive CD8+ T cells. This rapid gain of effector func-
tion was triggered by antigen-presenting LSECs, but not by
mature DCs. Such rapid LSEC-mediated expression of GzmB
in T cells was independent of conventional costimulatory signals
but required IL-6 trans-signaling. Mechanistically, IL-6 trans-
signaling together with TCR signaling was sufficient for direct
and rapid GzmB expression in T cells, thus identifying a unique
role for IL-6 trans-signaling in the development of effector
T cell function.
RESULTS
Naive CD8+ T Cells Rapidly Express Granzyme B after
Antigen Presentation by LSECs, but Not DCs
LSECs are potent antigen (cross)-presenting cells resident in the
liver. Whereas cross-priming by DCs requires several days for
cytotoxic effector T cell differentiation, cross-presentation by
LSECs to naive CD8+ T cells leads to an accelerated generation
of memory T cells (Bo¨ttcher et al., 2013). Here, we investigate the
early phase (i.e., the first 18 hr) of the interaction between cross-
presenting LSEC and naive CD8+ T cells compared to DCs.
Coculture of naive H-2Kb-restricted ovalbumin (OVA)-specific
TCR-transgenic CD8+ T cells (OT-I) with LSECs cross-present-
ing OVA resulted in rapid T cell activation. After 18 hr of
T cell contact with cross-presenting LSECs (LSEC-stimulated
T cells), increased expression levels of CD25, CD44, and CD69
were observed compared to T cells cultured with LSECs without
antigen (Figures 1A and 1B). Such increased expression of acti-
vation markers was indistinguishable from that following activa-
tion by cross-presenting mature DCs for 18 hr (DC-stimulated
T cells) (Figures 1A and 1B). Similarly, activation-induced reduc-
tion of CD62L expression was similar between LSEC- and
DC-stimulated T cells (Figures 1A and 1B). Although LSECs
and DCs were equally efficient in cross-presentation and initial
stimulation of naive OT-I T cells leading to expression of cyto-
kines such as IL-2, TNF, and IFNg during the first 12 hr (Fig-
ure 1C), we found one fundamental difference when analyzing
proteins important for T cell cytotoxic effector function. Stimula-
tion by cross-presenting LSECs within 18 hr led to strong upre-
gulation of the serine protease GzmB (Figure 1D), which is key
for cytolytic function of effector T cells (Heusel et al., 1994;
Trapani and Smyth, 2002). In contrast, cross-priming by matureCell ReDCs did not induce such rapid GzmB expression within 18 hr
(Figure 1D). This finding was corroborated by the prominent
upregulation of gzmb mRNA expression in LSEC-stimulated,
but not DC-stimulated, T cells within 18 hr (Figure 1E). Acquisi-
tion of GzmB expression and development of effector function
upon classical T cell priming by DCs was only observed after
T cells had proliferated (Figure 1F) (Curtsinger et al., 2005b;
van Stipdonk et al., 2001). The rapid GzmB expression in
LSEC-stimulated T cells, however, occurred before proliferation
started, since no carboxyfluorescein succinimidyl ester (CFSE)
dilution was observed in GzmB-expressing T cells (Figure 1F),
which suggests a distinct developmental process. Time kinetic
analysis of gzmb gene expression between T cells stimulated
by LSECs or DCs confirmed the rapid GzmB induction by
LSECs, but not DCs (Figure 1G). These experiments further
demonstrated that DC-stimulated T cells had sustained GzmB
expression after 48 hr, whereas gzmb levels in LSEC-stimulated
T cells declined to baseline at this point (Figure 1G). Taken
together, these results indicate a fundamental difference be-
tween LSECs and mature DCs in the dynamics of GzmB induc-
tion, namely a rapid but transient expression induced by LSECs
and a later but sustained expression induced by DCs. These two
time points (i.e., 18 hr and 48 hr) are referred to here as early and
late GzmB induction, respectively.
We next investigated whether antigen presentation in vivo
also led to rapid GzmB expression in T cells. We adoptively
transferred fluorescence-activated cell-sorted CD45.1+ naive
CD44lowCD62L+ OT-I T cells into CD45.2+ recipients and chal-
lenged these mice with soluble endotoxin-free OVA. After 18 hr,
GzmB-positive OT-I T cells were observed in liver, but not
lymphoid, tissues (Figure 1H). Consistent with their antigen-
specific activation, GzmB-positive T cells also expressed acti-
vation markers such as CD44 and CD69 (not shown). Not all
transferred T cells isolated from the liver showed increased
GzmB expression, which may relate to the fact that in vivo,
only some naive T cells engage in closer interaction with
cross-presenting LSECs in hepatic sinusoids (von Oppen
et al., 2009). Since we transferred only naive CFSE-labeled
CD44low T cells, we can exclude that rapid GzmB induction
in vivo resulted from reactivation of CD44+ memory T cells.
GzmB-positive T cells isolated from liver had not entered the
cell cycle, as demonstrated by the absence of CFSE dilution
(Figure 1I), similar to LSEC-stimulated GzmB-positive T cells
in vitro. These results suggested that LSECs cross-presenting
OVA in vivo could be responsible for the rapid GzmB induction
in naive OT-I T cells. To address this question, we used a
chimeric mouse model where H-2Kb expression is restricted
to nonmyeloid cells (bm1/C57BL/6), which together with the
injection of endotoxin-free OVA restricts cross-presentation to
liver-resident LSECs in vivo (Bo¨ttcher et al., 2013; von Oppen
et al., 2009). Transfer of fluorescence-activated cell-sorted
naive OT-I T cells into (bm1/C57BL/6) chimeric mice followed
by injection of endotoxin-free OVA resulted in GzmB induction in
T cells isolated 18 hr later from liver that was indistinguishable
from T cells stimulated in wild-type mice with ubiquitous H-2Kb
expression (Figure 1J). No GzmB expression was observed
18 hr after T cell transfer into OVA-challenged (C57BL/6/
bm1) chimeric mice, where only bone marrow-derived APCs,ports 8, 1318–1327, September 11, 2014 ª2014 The Authors 1319
Figure 1. CD8+ T Cell Stimulation by Cross-
Presenting LSECs, but Not DCs, Leads to
Rapid GzmB Induction
(A–E) Analysis of naive OT-I T cell activation 18 hr
after in vitro coculture with OVA-cross-presenting
LSECs or mature DCs. T cells cultured on LSECs
without OVA served as control. (A) Flow cytometric
analysis and (B) quantification of surface marker
expression. (C) OT-I T cells were cocultured with
OVA-loaded splenic DCs or OVA-loaded LSECs for
3–12 hr in vitro. Production of T cell effector cyto-
kines IFNg, IL-2, and TNF was analyzed by ELISA.
Data pooled from two or three independent
experiments are shown, and error bars depict
mean ± SD. (D) Intracellular GzmB protein. (E)
Quantification of gzmB mRNA levels.
(F) Analysis of GzmB expression and proliferation
in CFSE-labeled T cells.
(G) Time kinetic of gzmB mRNA expression in
LSEC- or DC-stimulated T cells.
(H and I) Adoptive transfer of fluorescence-
activated cell-sorted naive CD45.1+CD44low OT-I
T cells labeled with CFSE into C57BL/6 wild-type
mice receiving 1 mg endotoxin-free OVA. (H)
Frequency of GzmB+ CD45.1+ T cells and (I) anal-
ysis of GzmB expression versus CFSE dilution
in CD45.1+ T cells from the liver 18 hr after OVA
application.
(J) GzmB expression in transferred CD45.1+ OT-I
T cells 18 hr after antigen-specific priming
in C57BL/6 wild-type mice, [bm1- > C57BL/6]
chimeric mice, or [C57BL/6- > bm1] chimeric mice
in vivo. For (B), (E), (G), and (J), data pooled from
two to four separate experiments are shown and
error bars depict mean ± SEM. In (A), (D), (F), and
(I), flow cytometric graphs representative of at least
three independent experiments are shown.but not LSECs, cross-present circulating OVA (Figure 1J).
Taken together, these results support the notion that LSEC
cross-presentation leads to a unique differentiation process
in naive CD8+ T cells characterized by rapid GzmB induction
within 18 hr.1320 Cell Reports 8, 1318–1327, September 11, 2014 ª2014 The AuthorsLSEC-Stimulated GmzB-Positive T
Cells Gain Effector Functions
Analysis of GzmB expression suggested
that naive T cells stimulated by cross-
presenting LSEC rapidly gained cytotoxic
effector function. Consistent with this
assumption, TCR restimulation of LSEC-
stimulated T cells in vitro resulted in
localization of LAMP1 molecules to the
cell surface (Figure 2A), indicating that
LSEC-stimulated T cells have the poten-
tial to secrete GzmB from intracellular
stores (Blott and Griffiths, 2002). LSEC-
stimulated GzmB-expressing T cells effi-
ciently killed peptide-loaded target cells,
whereas unloaded control cells were
not affected (Figure 2B). The rapid devel-
opment of antigen-specific cytotoxicitywithin 18 hr required cross-presentation, because OT-I T cells
cocultured with LSECs in the absence of OVA did not kill target
cells (Figure 2B). In contrast, DC-stimulated T cells were
not cytotoxic at 18 hr after T cell priming (Figure 2B) but ac-
quired cytotoxic function later (Figure 2C). This suggests
Figure 2. Rapid Acquisition of Effector
Functions in LSEC-Stimulated T Cells
(A) Flow cytometric quantification of anti-
CD3 induced externalization of LAMP1 surface
expression on OT-I T cells cultured with cross-
presenting LSECs for 18 hr.
(B and C) Antigen-specific T cell cytotoxicity after
18 hr (B) or 72 hr (C) of coculture with cross-
presenting LSECs or DCs.
(D–J) Time kinetic analysis of cytokine release
by ELISA (D–F) and flow cytometric analysis of
expression of T-box transcription factors Eomes
and T-bet (G–J) in OT-I T cells cocultured with
cross-presenting splenic DCs or LSECs. In (B), (C),
(H), and (J), data from one out of three separate
experiments are shown as mean ± SD. In (A),
(D)–(G), and (I), data pooled from three to four
experiments are shown and error bars represent
mean ± SEM.that development of effector T cell functions occurs via
different means through cross-presenting LSECs compared to
mature DCs.
Cytotoxic CD8+ T cells are known to also secrete effector
cytokines such as IFNg, IL-2, and TNF (Zhang and Bevan,
2011). LSEC-stimulated GzmB-positive T cells, despite their
potent cytotoxic function, did not produce significant amounts
of IFNg, IL-2, or TNF compared to DC-stimulated T cells (Figures
2D–2F), demonstrating that cytokine production does not corre-
late with rapid acquisition of cytotoxicity. The T-box transcription
factors T-bet and Eomes are involved in cytotoxic T cell differen-
tiation by mature DCs (Cruz-Guilloty et al., 2009; Intlekofer et al.,
2005; Pearce et al., 2003). During the first 18 hr of T cell stimula-
tion by LSECs or mature DCs, no difference in expression
of Eomes or T-bet was observed (Figures 2G and 2H). After
4 days, however, we found a reciprocal regulation of these
two transcription factors, i.e., increased Eomes expression in
LSEC-stimulated T cells and increased T-bet expression in
DC-stimulated T cells (Figures 2I and 2J). While these results
confirm previous reports on the regulation of T-bet and EomesCell Reports 8, 1318–1327, Sepexpression during canonical cytotoxic
T cell differentiation (Bo¨ttcher et al.,
2013; Intlekofer et al., 2005; Rao et al.,
2010), they suggest that rapid GzmB
expression and cytotoxic function in
LSEC-stimulated T cells may not depend
on T-bet or Eomes.
IL-6 trans-Signaling Elicits Early
GzmB Expression in T Cells
Wewondered which signals were respon-
sible for LSEC-induced rapid expression
of GzmB in T cells. We first investi-
gated the contribution of TCR signaling
strength. LSECs and DCs were equally
efficient in cross-presentation over a
wideOVAconcentration range (Figure3A),
i.e., delivery of signals through the TCR.However, augmenting antigen concentrations did not result
in rapid GzmB induction in DC-stimulated T cells (Figure 3B).
Notwithstanding the direct correlation of TCR activation and
GzmB induction in LSEC-stimulated T cells, the results therefore
indicate that the extent of TCR signaling alone does not deter-
mine rapid GzmB upregulation in T cells. It rather suggested
that LSECs provided a distinct signal to T cells for rapid GzmB
induction within 18 hr that is not provided by mature DCs.
We therefore analyzed the contribution of cosignaling mole-
cules to rapid GzmB induction in LSEC-stimulated T cells.
Even in the absence of CD28 signals, in T cells stimulated by
cross-presenting CD80/86dko LSECs, we observed a robust
induction of rapid GzmB expression (Figure 3C). Similarly,
neutralizing antibodies blocking the interaction between recep-
tor-ligand pairs relevant for T cell costimulation, such as
4-1BB–4-1BBL, CD40-CD40L, CD70-CD27 or OX40–OX40L,
or ICAM-1 did not influence LSEC-induced rapid GzmB expres-
sion (Figure 3D). Interestingly, blockade of the coinhibitory re-
ceptor PD-1, which controls TCR signaling (Francisco et al.,
2010), also did not increase GzmB expression levels (Figure 3D),tember 11, 2014 ª2014 The Authors 1321
Figure 3. Rapid GzmB Induction in T Cells Is Mediated by IL-6 trans-signaling
(A) Cross-presentation determined by IL-2 release from T cells measured by ELISA.
(B) Antigen dose kinetic of GzmB expression in LSEC- or DC-stimulated T cells.
(C) GzmB expression in T cells stimulated by wild-type or CD80/86dko cross-presenting LSECs.
(D–H) Flow cytometric determination of GzmB expression in T cells stimulated by LSECs in the presence of neutralizing antibodies for 18 hr (D–G) or by mature
DCs for 72 hr (H).
(legend continued on next page)
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strengthening again the notion that GzmB expression in LSEC-
stimulated T cells was not regulated by the strength of TCR
signaling.
Next, we analyzed the contribution of soluble mediators that
serve as cosignaling molecules for T cell activation (Curtsinger
and Mescher, 2010). Blockade of IL-12 did not affect GzmB
expression (Figure 3E), consistent with lack of IL-12 expression
by LSECs (Kern et al., 2010). Similarly, neutralization of type I
IFN using anti-IFN alpha receptor antibodies did not modify
GzmB expression levels in LSEC-stimulated T cells (Figure 3E).
To exclude redundant functions of these cosignaling molecules,
we simultaneously blocked CD28, IL-12, and type I IFN signals.
This concurrent blockade did not influence rapid LSEC-medi-
ated GzmB induction in T cells (Figure 3F). Also, blockade of
other soluble mediators known to enhance T cell effector func-
tions (Freeman et al., 2012), i.e., IFNg or IL-15, had no effect,
but blocking IL-2 strongly reduced rapid GzmB induction in
LSEC-stimulated T cells (Figure 3G). Whereas CD28 signaling
was dispensable for rapid GzmB induction in LSEC-stimulated
T cells (see Figure 3C), it was crucial for late GzmB induction in
DC-stimulated T cells (Figure 3H). Neutralization of IL-2 also
impaired late GzmB induction in DC-stimulated T cells (Fig-
ure 3H). Supplementation of cocultures of mature antigen-pre-
senting DCs and T cells with exogenous IL-2 did not enable rapid
GzmB induction in T cells within 18 hr (Figure 3I), which suggests
that IL-2 is not sufficient for early GzmB induction but rather acts
as a cofactor. Since we observed that LSECs and DCs released
large concentrations of IL-6 during cross-presentation to naive
T cells (not shown), we tested whether IL-6 signaling was
involved in rapid GzmB induction. IL-6 classic signaling requires
the presence of IL-6R and the ubiquitously expressed signaling
transducing unit gp130. Cells that do not express membrane-
bound IL-6R can be activated through IL-6 trans-signaling, a
processwhereby the complex of IL-6/sIL-6R triggers gp130 acti-
vation (Jones et al., 2011). Neutralization of IL-6 or blockade of
the IL-6R both abrogated rapid GzmB-induction in LSEC-stimu-
lated T cells (Figure 3J), raising the question whether classical or
IL-6 trans-signaling was involved. The addition of soluble gp130
(sgp130Fc) to cocultures of cross-presenting LSECs and naive
T cells did not abrogate rapid GzmB induction (Figure 3J),
although trans-signaling by soluble IL-6/IL-6R complexes is
completely blocked by sgp130Fc (Jones et al., 2011). We there-
fore determined whether IL-6R expression on cells in trans could
also lead to IL-6 signaling on an IL-6R-deficient cell population,
such as CD8+ T cells (Jones et al., 2011). To address this issue,
we used Ba/F3 cells stably transduced with either gp130 (Ba/F3-(I) Influence of exogenous IL-2 (10 ng/ml) or stimulatory anti-CD28 antibody (10
(J) Impact of neutralizing antibodies blocking IL-6 or IL-6R-signaling on rapid Gz
(K) Proliferation of Ba/F3-IL-6R or Ba/F3-gp130-eGFP cells after 2 days of in vitro
and 1 mg/ml Sgp130Fc. Murine IL-3 served as a positive control.
(M–O) GzmB expression in T cells 18 hr after stimulation by (K and L) cross-presen
IL-6 or hyper-IL-6. For (K) and (M), IL-6 and hyper-IL-6were used at 5 ng/ml and Sg
are shown as mean ± SD.
(P) Analysis of GzmB expression in OT-I T cells 18 hr after stimulation by CD3/2
leukemia inhibitory factor (LIF), each at 1–100 ng/ml. Stimulation with CD3/CD2
sentative of two independent experiments is shown as mean ± SD.
(Q) Intracellular expression of phospho-STAT3 18 hr after stimulation of naive O
supplemented with 5 ng/ml hyper-IL-6. Data are representative of two independ
Cell Regp130) or IL-6R (Ba/F3-IL-6R). Whereas Ba/F3-gp130 cells only
proliferated in response to hyper-IL-6, but not IL-6 alone (Fig-
ure 3K), the addition of IL-6 to Ba/F3-gp130 cells cocultured
together with Ba/F3-IL-6R cells was sufficient to induce prolifer-
ation in Ba/F3-gp130 cells (Figure 3L). Furthermore, such prolif-
eration even occurred in the presence of sgp130Fc (Figure 3L).
These data indicate that not only soluble IL-6/IL-6R complex
but also surface-bound IL-6/IL-6R was sufficient to induce IL-6
trans-signaling in IL-6R-deficient cells. If IL-6 trans-signaling
was relevant for rapid GzmB-induction, then IL-6 coupled to its
receptor (hyper-IL-6) should lead to GzmB induction in T cells
stimulated by antigen-presenting DCs. Indeed, addition of hy-
per-IL-6, but not IL-6 alone, triggered GzmB expression within
18 hr in DC-stimulated T cells (Figures 3M and 3N). The addition
of hyper-IL-6 to anti-CD3/CD28-coated microbeads as artificial
APCs also induced GzmB expression within 18 hr (Figure 3O),
which demonstrates that IL-6 trans-signaling acting on T cells
was required and sufficient to drive rapid development of
effector functions. Interestingly, other ligands for gp130 such
as oncostatin M (OSM) or leukemia inhibitory factor (LIF) failed
to induce GzmB expression (Figure 3P). Furthermore, hyper-
IL-6 treatment induced STAT3 phosphorylation in T cells in com-
bination with anti-CD3/CD28-coated microbeads within 18 hr,
whereas LSEC-stimulated T cells only showed a nonsignificant
increase in STAT3 phosphorylation (Figure 3Q). These results
indicate that hyper-IL-6 initiates an as-yet-undefined signaling
cascade relevant for rapid effector T cell differentiation that
needs to be further identified in the future.
Rapid Acquisition of Effector Cell Function Attributes
Superior Activation Potential to T Cells
Next, we asked whether the rapid but transient induction of
effector T cell function by LSECs (see Figure 1) changed the
responsiveness toward further stimulation. Whereas GzmB
expression declined in LSEC-stimulated T cells over time (see
Figure 1), reactivation of these T cells 18 hr after their initial
stimulation through LSECs by mature DCs or anti-CD3/CD28
microbeads led to a sustained and further increase in GzmB
expression over several days (Figures 4A and 4B). During such
treatment, naive T cells required more than 48 hr to reach similar
levels of GzmB expression compared to LSEC-stimulated T cells
(Figures 4A and 4B). Also, IFNg expression was increased upon
such reactivation of LSEC-stimulated T cells (Figures 4C and
4D). These findings were confirmed by challenge of T cells stim-
ulated by LSECs for 18 hr or naive T cells with phorbol myristate
acetate (PMA)/ionomycin followed by determination of cytokinemg/ml) on GzmB expression in DC-stimulated T cells after 18 hr.
mB induction in LSEC-stimulated T cells.
culture in the presence of human IL-6, hyper-IL-6 (both 10 ng/ml), or hyper-IL-6
tingmature DCs or (M) anti-CD3/28microbeads supplementedwith exogenous
p130Fcwas used at 10 mg/ml. Data from one of three independent experiments
8 microbeads supplemented with the gp130-ligands oncostatin M (OSM) and
8 beads plus 5 ng/ml hyper-IL-6 served as positive control. Data are repre-
T-I T cells with OVA-loaded LSECs, OVA-loaded DCs, or OVA-loaded DCs
ent experiments and shown as mean ± SD.
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Figure 4. LSEC-Stimulated GzmB-Expressing T Cells Are Responsive to Further Stimulation
(A–D) Naive T cells or LSEC-stimulated GzmB-expressing T cells (after 18 hr) were restimulated with cross-presenting mature DCs (A and C) or anti-CD3/28
microbeads (B and D) for 3 days and analyzed for GzmB (A and B) or IFNg expression (C and D) after restimulation with PMA/ionomycin.
(E and F) IL-2 (E) and IFNg (F) production 4 hr after PMA/ionomycin restimulation of LSEC-stimulated GzmB-positive T cells.
(G) Expansion (fold increase) of naive or LSEC-stimulated GzmB-expressing T cells after 3 days of stimulation with anti-CD3/28 microbeads or cross-presenting
mature DCs.
(H and I) Increase in GzmB (H) or IFNg production (I) in naive or LSEC-stimulated GzmB-expressing T cells after 8 hr incubation with inflammatory cytokines. The
increase in MFI compared to unstimulated T cells is shown. Data from one of three independent experiments are shown; error bars depict mean ± SD.production within 4 hr. Under these conditions, LSEC-stimulated
T cells showed strong expression of IL-2 and IFNg, whereas
naive T cells did not produce any cytokines (Figures 4E and
4F), demonstrating that GzmB-expressing T cells are more
responsive to reactivation than naive T cells. Such increased
IL-2 expression together with expression of its receptor CD25
(see Figure 1) suggested a capacity for rapid proliferation.
Indeed, LSEC-stimulated T cells showed vigorous expansion
within 72 hr of restimulation with antigen-presenting DCs or
anti-CD3/CD28 microbeads that were more prominent than
proliferation of naive T cells (Figure 4G).
T cell effector function is triggered by antigen-specific stimula-
tion but can also be evoked by cytokines released during inflam-
mation in an antigen-independent fashion (Berg et al., 2003;1324 Cell Reports 8, 1318–1327, September 11, 2014 ª2014 The AuFreeman et al., 2012; Raue´ et al., 2004).We therefore determined
whether LSEC-stimulated T cells were susceptible for such
‘‘innate activation’’ by inflammatory cytokines. Indeed, we
observed a further upregulation of GzmB expression if LSEC-
stimulated T cells were incubated with type I IFN or hyper-IL-6
in the absence of antigen (Figure 4H) and a moderate upregula-
tion of GzmB expression upon incubation with IFNg, IL-12, IL-18,
or IL-33 but no effect upon incubation with IL-2 or IL-15 (Fig-
ure 4H). Importantly, naive OT-I T cells did not show any GzmB
expression under these conditions (Figure 4H). Likewise, both
IL-12 and type I IFN evoked production of the T cell effector cyto-
kine IFNg in LSEC-stimulated T cells, but not in naive T cells (Fig-
ure 4I). These results indicate that rapid induction of effector
T cell functions by cross-presenting LSECs in the liver maythors
provide an advantage to mount protective immunity against sys-
temically circulating pathogens.
DISCUSSION
Mature DCs are well known to provide costimulatory signals
that initiate development of naive CD8+ T cells into functional
cytotoxic effector T cells (Zhang and Bevan, 2011). In particular,
certain stimulatory cytokines like interferons and IL-12 are
crucial for the acquisition of T cell effector function like GzmB
expression and IFNg production (Curtsinger and Mescher,
2010). This developmental process takes at least 48 hr and
correlates with T cell proliferation (Curtsinger et al., 2005a;
van Stipdonk et al., 2001). Here, we report the existence of an
as-yet-unrecognized developmental process for generation of
effector T cells, which occurs much faster and independent of
those conventional stimulatory signals through signals delivered
by nonimmune antigen-presenting cells. Naive CD8+ T cells
stimulated by cross-presenting LSECs acquired within 18 hr
transient GzmB expression and killed target cells in an anti-
gen-specific fashion. Although we could not provide formal
evidence for expression of perforin, the combination of GzmB
induction and the ability to kill target cells strongly suggests
that LSEC-primed T cells have a cytotoxic effector function.
Such rapid induction of GzmB expression occurred together
with a rapidly induced production of cytokines, preceded
T cell proliferation, and was independent of signaling through
CD28, IL-12R, or IFN alpha receptor. Since T-box transcription
factors were not differentially regulated between LSEC-stimu-
lated and DC-stimulated T cells at this early time point, a critical
contribution of these factors to rapid GzmB induction appears
unlikely, although we have not provided formal evidence for
this here. Inhibition of other less prominent costimulatory sig-
nals such as 4-1BB or OX40 also did not contribute to this rapid
GzmB induction. However, we found that IL-2 was necessary,
but not sufficient, for rapid GzmB induction, indicating that
IL-2 may serve as an important cofactor. Taken together, these
results suggest the existence of another LSEC-derived mediator
triggering rapid GzmB induction.
We discovered that IL-6 trans-signaling was required for
LSEC-induced rapid GzmB induction in T cells and was also
sufficient to establish rapid GzmB expression in T cells when
coadministered together with cross-presenting DCs. LSECs
produced IL-6 during cross-presentation and stimulation of
naive CD8+ T cells. IL-6 signaling is only initiated upon associ-
ation with the IL-6R and binding to the ubiquitously expressed
gp130. Since CD8+ T cells do not express IL-6R, trans-
signaling through soluble hyper-IL-6 (i.e., IL-6 complexed to
the IL-6R) is the only means to establish proinflammatory IL-6
signaling in these cells (Rose-John, 2012). Since 50 to 100 IL-
6/IL-6R complexes suffice to initiate trans-signaling (Jones
et al., 2011), it is difficult to directly demonstrate expression
of these complexes on the surface of CD8+ T cells stimulated
by cross-presenting LSECs. However, hyper-IL-6, but not other
gp130 ligands such as OSM or LIF in combination with anti-
CD3/28-coated microbeads, sufficed to induce rapid GzmB
expression in naive CD8+ T cells, demonstrating that IL-6
trans-signaling directly acts on T cells. The complementationCell Reof conventional vaccine protocols with hyper-IL-6 may there-
fore provide an additional benefit by rapid induction of effector
functions in combination with the conventional developmental
process for the acquisition of cytotoxic T cell effector function
by mature DCs.
After several days, LSEC-stimulated T cells resemble central
memory T cells with respect to their localization in lymphoid tis-
sue and their requirements for activation and generation of new
effector T cells during a recall response (Bo¨ttcher et al., 2013).
The rapid GzmB induction during the first 18 hr of contact with
LSECs may therefore represent an intermediate developmental
stage or may serve a particular function during immune re-
sponses initiated locally in the liver. It seems unlikely, however,
that transient acquisition of cytotoxicity may serve any direct
function given the low frequencies of particular antigen-specific
CD8+ T cells. Nevertheless, similar to cytokine-induced activa-
tion of certain memory T cell populations (Berg et al., 2003;
Kupz et al., 2012; Soudja et al., 2012), we found that contact
with inflammatory mediators such as interferons or antigen-spe-
cific restimulation of GzmB-positive LSEC-stimulated T cells
prolonged GzmB expression and led to strong T cell prolifera-
tion. Since LSEC-stimulated T cells rapidly relocate from the liver
to lymphoid tissues via CCR7 and CD62L (Bo¨ttcher et al., 2013),
it is possible that these cells predominantly exert their effector
functions in lymphoid tissues. As LSEC-stimulated T cells upre-
gulate CXCR3 (Bo¨ttcher et al., 2013) and CXCR3-expressing
T cells are critical for defense against microbial infections in
the subcapsular region of lymph nodes (Kastenmu¨ller et al.,
2012), LSEC-stimulated T cells may contribute to antimicrobial
defense in the lymph node rather than in the liver.
Taken together, rapidgeneration ofGzmB-positive T cells in the
liver may constitute an as-yet-unrecognized arm of antigen-spe-
cific immunity against pathogens that are systemically distributed
and whose antigens are cross-presented by LSECs, like viruses
infecting the liver or lung. The rapid yet transient induction of
effector functions in LSEC-stimulated T cells is consistent with
our previous observation that these cells at later time points are
nonresponsive to restimulation via the TCR (Diehl et al., 2008)
but showmemory-like functions to support anti-infectious immu-
nity upon combinatorial restimulation through the TCR and costi-
mulatory molecules (Bo¨ttcher et al., 2013). The knowledge of the
importance of IL-6 trans-signaling for this rapid generation of
T cells with effector functionsmay help to implement novel vacci-
nation strategies to increase the efficiency of protective immunity.
EXPERIMENTAL PROCEDURES
Mice
B6.CH-2bm1, CD80/86dko, C57BL/6, CD90.1+ C57BL/6, TCR transgenic OT-I,
and CD45.1+ OT-I mice were bred under specific-pathogen-free (SPF) condi-
tions in the central animal facility of the University Hospital Bonn. Chimeric
animals were generated as described previously (von Oppen et al., 2009).
Mice were kept under SPF conditions, and in vivo experiments were approved
by the local animal care commission.
Analysis of T Cell Priming In Vivo
Splenic OT-I T cells were enriched by autoMACS using the untouched CD8
T cell isolation kit (Miltenyi), and CD8+CD45.1+CD44low OT-I T cells were
sorted by fluorescence-activated cell sorting (FACS). A total of 1 3 106 were
injected intravenously into C57BL/6 wild-typemice or chimeric animals, whichports 8, 1318–1327, September 11, 2014 ª2014 The Authors 1325
received 1 mg endotoxin-free OVA (Hyglos). Then, 18 hr later, lymphocytes
from spleen, liver, or lymph nodes were purified as described previously
(Bo¨ttcher et al., 2013), and the expression of GzmB was analyzed within
CD3+CD8+CD45.1+ T cells. In some experiments, fluorescence-activated
cell-sorted naive T cells were labeled with CFSE prior to adoptive transfer.
Ba/F3 Cell Experiments
Ba/F3 cells were stably transduced with human IL-6R cDNA and Ba/F3-gp130
cells with enhanced GFP cDNA as described (Ketteler et al., 2002). Expression
and purification of IL-6, hyper-IL-6, and sgp130Fc has been described previ-
ously (Fischer et al., 1997; Mackiewicz et al., 1992). For the coculture experi-
ment, 5 3 104 cells were cultivated at the indicated ratios for 2 days. Cell
viability was determined with Cell Titer Blue Cell viability assay reagent (Prom-
ega) following the manufacturer’s protocol.
Cell Isolation and Coculture Experiments
Dendritic cells or naive OT-I T cells used in in vitro coculture experiments were
isolated from spleen and purified by autoMACS (Miltenyi Biotec). LSECs were
isolated by gradient centrifugation followed by immunomagnetic sorting
(CD146) (Diehl et al., 2008). Cocultures of naive OT-I cells with LSECs or
mature DCs were conducted as described previously (Bo¨ttcher et al., 2013).
LSECs or mature DCs were loaded with 100 mg/ml OVA, and OT-I T cells
were added to antigen-presenting cells in a ratio of 1:1. In some experiments,
OT-I T cells were labeled with 1 mMCFSE (Invitrogen) for 15min at 37Cprior to
the coculture assay. Determination of cross-presentation was done by incuba-
tion of OVA-loaded APCs with H-2Kb-restricted OVA-specific B3Z cells and
analysis of IL-2 release by ELISA after 20 hr. In some experiments, neutralizing
antibodies for 41BBL (clone TKS-1), CD40L (MR1), CD70 (FR70), OX40L
(RM134L), ICAM (YN1/1.7.4), PD-1 (J43), CD80 (16-10A1), CD86 (GL1), IL-6
(MP5-20F3), IL-6R (polyclonal, AF1830, R&D Systems), IFNg (XMG1.2),
IL-15 (A10.3), IL-2 (JES6-1A12), IL-12 (clone C17.8), or type I IFN signaling
(anti-mouse IFN alpha receptor 1, clone MAR1-5A3) were added to cocultures
at 10 mg/ml. In some experiments, stimulation of naive T cells bymature DCs or
anti-CD3/28microbeads was done after the addition of recombinant cytokines
IL-2, IL-6, hyper-IL-6 (HIL-6), or stimulating anti-CD28 antibody (10 mg/ml,
eBioscience).
Quantification of gzmB Gene Expression by Real-Time PCR
Total mRNA was isolated using the RNeasy Micro Kit (QIAGEN; including
DNase digestion) and transcribed reversely into cDNA using the AffinityScript
multiple-temperature reverse transcriptase (Stratagene). Real-time PCR was
performed using the absolute QPCR SYBR green PCRmix (Abgene) in combi-
nation with specific primers (QuantiTect primer assay; QIAGEN) for murine
GzmB and GAPDH. GAPDH was used as reference gene. All real-time PCR
reactions were performed in a C1000 Thermal Cycler (Bio-Rad).
Flow Cytometry and Fluorescence-Activated Cell Sorting
Flow cytometric analyses and assessment of mean fluorescence intensity
(MFI) were conducted with a LSR Fortessa or Canto II (BD Biosciences).
Data were analyzed using FlowJo software (Tree Star). LIVE/DEAD fixable
violet or near-IR dead cell stain kit (Invitrogen) was used to exclude dead cells
in all experiments, and anti-CD16/32 antibody (2.4G2) was used to block un-
specific antibody binding via Fc receptors. Antibodies were purchased from
Biolegend or eBioscience. The following antibodies were used: CD3 (17A2),
CD8a (clone 53-6.7), CD25 (3C7), CD27 (LG.7F9), CD44 (IM7), CD45.1 (A20),
CD62L (MEL-14), CD69 (H1.2 F3), CD90.2 (HIS51), H-2Kb (5F1), and Lamp1
(1DB4). For intracellular staining of cytokines, cells were fixed in 4% PFA
and intracellular staining by anti-IFNg antibodies (XMG1.2) or anti-IL-2 anti-
bodies (JES6-5H4) was performed in permeabilization buffer (eBioscience)
for 30 min. Staining of T-bet (eBio4B10), Eomes (Dan11mag), or granzyme B
(anti-human, cross-reactive with mouse, clone GB11) was performed using
the Foxp3/transcription factor staining buffer set from eBioscience. Quantifi-
cation of total T cell numbers was donewith fluorochrome-labeledmicrobeads
(CountBright absolute counting beads; Life Technologies, Invitrogen). FACS
of naive T cells was performed with a DIVA cell sorter (BD). Expression
of phospho-STAT3 was determined by flow cytometry after intracellular
staining with anti-STAT3pY705 (clone4/P-STAT3) using the phosflow kit1326 Cell Reports 8, 1318–1327, September 11, 2014 ª2014 The Aufrom Becton Dickinson. Staining with the corresponding isotype antibody
served as control.
Analysis of T Cell Effector Functions
Analysis of GzmB expression was performed directly after isolation of T cells
ex vivo or from in vitro cocultures without further stimulation. T cell coculture
with anti-CD3/CD28 microbeads (Invitrogen) was done in the presence of re-
combinant mouse IL-2 and IL-12 (5 ng/ml). In order to determine the potential
of T cells to produce effector cytokines (see Figures 4E and F), T cells were
stimulated with PMA (5 ng/ml; Sigma Aldrich) and ionomycin (200 ng/ml,
Sigma Aldrich). To analyze T cell proliferation, naive CD8+ T cells were labeled
with 1 mMCFSE (Invitrogen) before coculture experiments or adoptive transfer,
and CFSE-dilution was measured by flow cytometry. Analysis of cytokine-
mediated T cell activation was done by incubating purified T cells for 8 hr at
37C with cytokines IL-2, IL-15, IL-18, IL-33, IFN-g, TNF (all 10 ng/ml), IL-12
(5 ng/ml), hyper-IL-6 (5 ng/ml), or IFNa (type 4, 1,000 U/ml) on CD90.1+ sple-
nocytes as feeder cells. Brefeldin A and monensin were added during the
last 2 hr of stimulation. Expression of GzmB and IFNg was subsequently
analyzed within CD90.2+ OT-I T cells by flow cytometry. Determination of an-
tigen-specific specific cytotoxicity was determined in vitro (Diehl et al., 2008).
Lipopolysaccharide-free OVA (Hyglos) was used for in vivo experiments at a
concentration of 1 mg/mouse.
Statistical Analysis
Data were compared using a one-way ANOVA or the unpaired two-tailed Stu-
dent’s t test. Data are shown as mean ± SEM or mean ± SD with *p < 0.05,
**p < 0.01, or ***p < 0.001.
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